123 related articles for article (PubMed ID: 7461266)
1. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
Pay GF; Wallis RB; Zelaschi D
Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
[No Abstract] [Full Text] [Related]
2. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
Pay GF; Wallis RB; Zelaschi D
Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
[TBL] [Abstract][Full Text] [Related]
3. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
Nunn B; James FJ
Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
[TBL] [Abstract][Full Text] [Related]
4. Relative effects of sulfinpyrazone and ibuprofen on canine platelet function and prostaglandin-mediated coronary vasodilation.
Goldstein RE; Davenport NJ; Capurro NL; Lipson LC; Bonow RO; Shulman NR; Epstein SE
J Cardiovasc Pharmacol; 1980; 2(4):399-409. PubMed ID: 6156338
[No Abstract] [Full Text] [Related]
5. Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.
Maguire ED; Pay GF; Wallis RB; White AM
Thromb Res; 1981 Feb; 21(3):321-7. PubMed ID: 7245142
[No Abstract] [Full Text] [Related]
6. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
Pedersen AK; FitzGerald GA
Clin Pharmacol Ther; 1985 Jan; 37(1):36-42. PubMed ID: 3917387
[TBL] [Abstract][Full Text] [Related]
7. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.
Chignard M; Wal F; Lefort J; Vargaftig BB
Eur J Pharmacol; 1982 Feb; 78(1):71-9. PubMed ID: 6804248
[TBL] [Abstract][Full Text] [Related]
8. A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig.
Butler KD; Wallis RB; White AM
Haemostasis; 1979; 8(3-5):353-60. PubMed ID: 159853
[TBL] [Abstract][Full Text] [Related]
9. Effects of sulfinpyrazone and its metabolite G25671 on platelet activation and desensitization and on bronchoconstriction induced by the prostaglandin endoperoxide analog U46619.
Hatmi M; del Maschio A; Lefort J; de gaetano G; Vargaftig BB; Cerletti C
J Pharmacol Exp Ther; 1987 May; 241(2):623-7. PubMed ID: 3106620
[TBL] [Abstract][Full Text] [Related]
10. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.
Del Maschio A; Livio M; Cerletti C; De Gaetano G
Eur J Pharmacol; 1984 Jun; 101(3-4):209-14. PubMed ID: 6432556
[TBL] [Abstract][Full Text] [Related]
12. The effect of sulphinpyrazone on the aggregation and release reactions of human platelets.
Wiley JS; Chesterman CN; Morgan FJ; Castaldi PA
Thromb Res; 1979 Jan; 14(1):23-33. PubMed ID: 570742
[No Abstract] [Full Text] [Related]
13. Sulphinpyrazone and indomethacin for inhibition of platelet prostaglandin synthesis.
Huijgens PC; van den Berg CA; Imandt LM; Langenhuijsen MM
Thromb Res; 1981 Nov; 24(3):267-70. PubMed ID: 7336383
[No Abstract] [Full Text] [Related]
14. Rat platelets aggregate in the absence of endogenous precursors of prostaglandin endoperoxides.
Bult H; Bonta IL
Nature; 1976 Dec; 264(5585):449-51. PubMed ID: 1004576
[No Abstract] [Full Text] [Related]
15. New vistas on the role of platelets in bronchoconstrictions.
Chignard M; Lefort J; Vargaftig BB
Agents Actions Suppl; 1979; (6):105-11. PubMed ID: 118655
[No Abstract] [Full Text] [Related]
16. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin.
Ali M; McDonald JW
J Lab Clin Med; 1977 Apr; 89(4):868-75. PubMed ID: 845486
[TBL] [Abstract][Full Text] [Related]
17. Effect of acetylsalicylic acid, sulfinpyrazone and their combination on collagen-induced platelet aggregation in guinea pigs.
Wong LT; Zawidzka Z; Thomas BH
Pharmacol Res Commun; 1978 Nov; 10(10):939-49. PubMed ID: 733865
[No Abstract] [Full Text] [Related]
18. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man.
Lorenz R; Siess W; Weber PC
Eur J Pharmacol; 1981 Apr; 70(4):511-8. PubMed ID: 7238575
[TBL] [Abstract][Full Text] [Related]
19. Malondialdehyde formation as an indicator of prostaglandin production by human platelets.
Smith JB; Ingerman CM; Silver MJ
J Lab Clin Med; 1976 Jul; 88(1):167-72. PubMed ID: 932533
[TBL] [Abstract][Full Text] [Related]
20. Correlation between inhibitory effect on platelet aggregation and disposition of sulfinpyrazone and its metabolites in rabbits. Part I: Single dose study.
Ritschel WA; Kuo BS
Biopharm Drug Dispos; 1987; 8(1):1-9. PubMed ID: 3107626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
